Vaxneuvance Side Effects
Generic name: pneumococcal 15-valent conjugate vaccine
Medically reviewed by Drugs.com. Last updated on May 8, 2023.
Note: This document contains side effect information about pneumococcal 15-valent conjugate vaccine. Some dosage forms listed on this page may not apply to the brand name Vaxneuvance.
Applies to pneumococcal 15-valent conjugate vaccine: intramuscular suspension.
Serious side effects of Vaxneuvance
Along with its needed effects, pneumococcal 15-valent conjugate vaccine (the active ingredient contained in Vaxneuvance) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking pneumococcal 15-valent conjugate vaccine:
Less common
Other side effects of Vaxneuvance
Some side effects of pneumococcal 15-valent conjugate vaccine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- decreased appetite
- difficulty in moving
- headache
- joint pain or swelling
- muscle aches, cramps, pains, or stiffness
- unusual tiredness or weakness
For Healthcare Professionals
Applies to pneumococcal 15-valent conjugate vaccine: intramuscular suspension.
General
The most commonly reported side effects included localized pain, irritability, elevated body temperature (from at least 38C to less than 39C), and somnolence.[Ref]
Dermatologic
Common (1% to 10%): Urticaria[Ref]
Local
Very common (10% or more): Localized pain (up to 75.8%), localized erythema (up to 21.6%), localized swelling (up to 21.7%), localized induration (up to 14.1%)
Uncommon (0.1% to 1%): Injection site urticaria[Ref]
Metabolic
Very common (10% or more): Decreased appetite (up to 19.4%)[Ref]
Musculoskeletal
Very common (10% or more): Myalgia (up to 28.8%), arthralgia (up to 12.7%)[Ref]
Nervous system
Very common (10% or more): Somnolence (up to 40.7%), headache (up to 26.5%)[Ref]
Other
Very common (10% or more): Elevated body temperature (at least 38C to less than 39C [up to 50.8%]), fatigue (up to 34.3%)
Common (1% to 10%): Elevated body temperature (at least 39C to less than 40C), elevated body temperature (at least 40C)[Ref]
Psychiatric
Very common (10% or more): Irritability (up to 55.1%)
Common (1% to 10%): Extreme distress, unable to do unusual activities[Ref]
More about Vaxneuvance (pneumococcal 15-valent conjugate vaccine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bacterial vaccines
- En español
Patient resources
Professional resources
Related treatment guides
References
1. Product Information. Vaxneuvance (pneumococcal 15-valent conjugate vaccine). Merck & Co., Inc. 2021.
2. Product Information. Vaxneuvance (pneumococcal 15-valent conjugate vaccine). Merck Sharp & Dohme (Australia) Pty Ltd. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.